Estrogen-receptor positive metastatic breast cancer often develops resistance to conventional therapies that severely lower a woman’s estrogen level. A group of researchers headed by a breast cancer specialist has found that in one-third of these cases, such tumors will respond, paradoxically, to therapy that raises a woman’s estrogen level.